"Our partnership with Innoforce will provide a powerful avenue to help clinical-stage therapeutic development programs from small and medium companies and to accelerate the pace of clinical development,” said Lingshi Tan, founder and chief executive officer, dMed.
The collaboration between the two companies will focus on advancing access to the latest innovative drugs for Chinese patients in addition to enhancing pharmaceutical manufacturing and development opportunities globally.
Yuling Li, chief executive officer, Innoforce, said, "Innovative biologic drugs, as well as cell and gene therapies, are the future drivers of biomedicine. The unique PDMO (partner development manufacturing organization) model that Innoforce is pioneering based on global quality manufacturing capabilities combined with our collaboration with dMed will bring the highest global standards to our partners' cutting-edge pharmaceutical research and development for China and the world."
Over the past 10 years, global demand for biologics has increased to 42% of the total clinical pipeline. In China alone, the anticipated growth rate for biopharmaceutical drugs is 15% over the next five years, with an estimated 1,000 biologics molecules in preclinical pipeline, many from new or emerging China-based companies.
The companies associated with the Innoforce and dMed collaboration will be housed on the Innoforce campus in Hangzhou, China. Central to the campus is Innforce CGTx Services, a contract development and manufacturing organization (CDMO) which provides commercially capable manufacturing platforms for gene and cell therapy products, and a biopharmaceutical manufacturing facility that supplies large-molecule drugs globally through Thermo Fisher Biopharma Services (Hangzhou) LTD, a joint venture between Innoforce and Thermo Fisher. The Innoforce campus is a gateway facilitating the commercialization of biopharmaceutical products in China, the U.S., Europe, and the rest of the world.